Ipamorelin
FDA describes route-specific uncertainty and serious events reported in an intravenous study.
Uncertainty is part of the safety picture.
FDA lists ipamorelin acetate in category 2 under its 503B interim policy. The agency identifies potential immunogenicity concerns from aggregation and impurities, plus characterization issues related to unnatural amino acids.
FDA cites serious adverse events, including death, in a published study involving intravenous administration for gastric motility. This does not establish the same outcome for every route or product.
FDA says it lacks enough information to know whether administration by certain other injectable routes would cause harm. A lack of safety information is not a safety assurance. We provide no dose, regimen or purchase recommendation.
Interpretation is limited to the source linked above. Independent medical review pending.